Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



On April 7, 2023, J. Roger Moody, Jr. notified Talis Biomedical Corporation (the
"Company") that he will step down as the Company's Chief Financial Officer,
effective as of the close of business on April 21, 2023, to accept a new role as
chief executive officer of another public company. Mr. Moody's resignation is
not as a result of any disagreement with the Company on any matter relating to
its operations, policies, or practices, or to any issues regarding its
accounting policies or practices.
The Board of Directors has appointed Rebecca Markovich to serve as interim Chief
Financial Officer of the Company, effective as of the close of business on April
21, 2023. The Company intends to conduct an executive search for a permanent
chief financial officer.
Prior to her appointment as interim Chief Financial Officer, Ms. Markovich, 50,
served as the Company's Vice President, Controller from May 2022 to present and
as the Company's Vice President, Accounting from January 2022 to May 2022. Prior
to joining the Company, Ms. Markovich was the Chief Financial Officer, Vice
President and Corporate Controller of ApiJect, a private equity-backed start-up
company focused on injectable drug delivery systems from 2021 to January 2022.
From 2019 to 2021, Ms. Markovich was the Vice President, Global Controller at
Vyaire, a private equity-backed global respiratory company previously spunout
from Becton Dickinson. Prior to Vyaire, Ms. Markovich was the Vice President,
Chief Accounting Officer and Controller for Cars.com, a public company and
leading digital marketplace and solutions provider for the automotive industry
that connects car shoppers with sellers. Ms. Markovich is a graduate of Indiana
University where she obtained a B.S. degree in Accounting from the Kelley School
of Business. She is also an Illinois Certified Public Accountant.
There is no arrangement or understanding between Ms. Markovich and any other
person pursuant to which she was appointed as Chief Financial Officer. Further,
with regard to Ms. Markovich, there are no transactions since the beginning of
the Company's last fiscal year, or any currently proposed transaction, in which
the Company is a participant that would require disclosure under Item 404(a) of
Regulation S-K promulgated by the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
Exhibit Number   Exhibit Title
104              Cover Page Interactive Data File (Embedded within the Inline XBRL
                 document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses